Chief Executive Officer
30+ experience in Clinical Research where she has managed successful cross-functional teams and implemented development plans for 15 marketed compounds. Leading disruptive innovation teams at pharmaceutical companies to deliver on initiatives that strengthen product portfolios. Areas of expertise: Rare Diseases including ADPKD, Schizophrenia, Alzheimer’s, PTSD, Pain Management, Reproductive Health, and Cardio/Renal (CHF, Hyponatremia, CKD).
- CEO/Founder, Innovenn – We leverage the latest advances in artificial intelligence and strong engineering foundations to guide development of software that is regulated as a medical device (SaMD) and to enable launch of disruptive health solutions (Drug & Device) to improve health outcomes.
- CEO/Founder, Improvita – Addressing Human Factors, Usability Engineering and User Experience (HF/UE/UX) requirements differentiate your product from the competition while addressing the U.S. and international regulatory Human Factors testing requirements and standards.
- Owner, Innovenn Life Science Consulting (formerly Cogent Pharma) -Multiple therapeutic areas/drug development consulting from IND to NDA defense.
- Senior Clinical Manager, Clinical Development, Merck
Bachelor of Science: Seattle University